The future of cancer diagnostics lies in speed, accuracy, and AI-driven automation, and Qritive is leading this transformation. Founded in 2017 by Dr. Aneesh Sathe, this Singapore-based startup leverages artificial intelligence to enhance pathology assessments, enabling faster and more precise cancer detection. By integrating automated slide analysis and deep learning algorithms, Qritive helps healthcare professionals streamline workflows and improve patient outcomes. With $9 million in funding, including a $7.5 million Series A round in 2023, the company is poised to redefine cancer diagnostics worldwide.
Revolutionizing Cancer Diagnosis with AI
Founded in 2017 by Dr. Aneesh Sathe, Qritive is a health-tech startup based in Singapore specializing in AI-powered cancer diagnostics. The company leverages artificial intelligence to improve the speed, accuracy, and cost-efficiency of pathology assessments, enabling early cancer detection and enhancing patient outcomes.
Traditional pathology relies heavily on manual analysis, which can be slow and prone to human error. Qritive’s AI-driven technology automates this process, allowing hospitals and laboratories to achieve more precise and rapid diagnoses. This innovation is particularly vital in addressing global shortages of trained pathologists and improving cancer survival rates.
Enhancing Medical Efficiency with AI
Qritive’s platform integrates machine learning algorithms to scan and interpret pathology slides, reducing diagnostic time from days to hours. The AI models can identify cancerous tissues, classify tumor types, and provide real-time insights, assisting medical professionals in making more informed decisions.
In January 2023, Qritive raised $7.5 million in Series A funding, bringing its total funding to $9 million. The funding round was backed by four investors, demonstrating strong market confidence in the company’s AI-driven approach. Today, Qritive is valued at $45 million and continues to enhance its deep learning models for improved accuracy.
Scaling Innovations for a Better Future
Qritive is expanding its partnerships with hospitals, diagnostic centers, and pharmaceutical companies, integrating its technology into global healthcare networks. The company is also developing cloud-based pathology solutions, allowing doctors to remotely access AI-assisted diagnostics, ensuring broader accessibility.
With an increasing focus on AI-powered healthcare, Qritive is well-positioned to become a leader in digital pathology, transforming how cancer is diagnosed and treated worldwide.
To read more startup stories visit- hsingaporebusinessedge
